Mechanism of action
Oseltamivir is a prodrug carboxylate ester that is hydrolyzed by hepatic esterases to its active form, oseltamivir carboxylate (OC). OC is a competitive inhibitor of influenza viral neuraminidase, a sialidase glycoprotein on the viral envelope.
Neuraminidase cleaves sialic acid receptors on the host cell surface, allowing release of newly synthesized viral particles. By inhibiting this enzyme, oseltamivir prevents the release of progeny virions from infected respiratory epithelial cells, limiting viral spread and reducing viral load.
Oseltamivir is selective for influenza neuraminidase (particularly N1 and N2 subtypes) and shows activity against both influenza A and B. The drug does not prevent infection at the cellular level but reduces viral replication and shedding once infection is established.
- Oseltamivir blocks influenza neuraminidase, preventing viral release from infected cells; most effective within 48 hours of symptom onset.
- Active metabolite (oseltamivir carboxylate) is renally excreted; dose reduction required in renal impairment (CrCl <30 mL/min) to avoid neuropsychiatric toxicity.
- Neuropsychiatric events (confusion, delirium, self-injury) reported in children/adolescents; monitor behavior; causal relationship with drug vs. severe influenza unclear.
- H275Y mutation confers oseltamivir resistance in some H1N1 strains; resistance is uncommon but increasingly recognized globally.
- Nausea and vomiting are most common adverse effects; taking with food reduces gastrointestinal upset.
- Oseltamivir is a prodrug; hepatic esterases activate it to oseltamivir carboxylate; hepatic disease reduces activation.
- Do NOT give oseltamivir within 48 hours of live attenuated influenza vaccine (LAIV); inactivated vaccine is preferred during treatment.
- Oseltamivir is preferred over zanamivir in patients with asthma/COPD because it does not cause bronchospasm.
Indications
Treatment of acute influenza:
- Uncomplicated acute illness due to influenza A or B virus in patients ≥2 weeks old
- Most effective when initiated within 48 hours of symptom onset; reduces duration of illness by approximately 1 day and may reduce complications in high-risk patients
- Consider treatment beyond 48 hours in hospitalized patients with severe or progressive illness
Prophylaxis (post-exposure):
- Prevention of influenza in household contacts and other close contacts of confirmed or suspected influenza cases
- Dosing follows product label; typically 10 days post-exposure
Prophylaxis (seasonal):
- Recommended during influenza season for patients at high risk (elderly, pregnant, chronic medical conditions, immunocompromised) when vaccine is unavailable or contraindicated
- Not a substitute for annual influenza vaccination
Pharmacokinetics
Absorption: Oseltamivir phosphate is rapidly absorbed from the gastrointestinal tract. Peak plasma levels of active metabolite occur 2–3 hours after oral administration.
Distribution: Widely distributed to respiratory secretions and tissue. Active metabolite has limited CNS penetration due to polarity.
Metabolism: Oseltamivir is a prodrug; ~90% is converted to active oseltamivir carboxylate by hepatic and intestinal esterases. Minimal metabolism of the active form.
Elimination: Active metabolite is excreted unchanged primarily in urine (>90%). Renal elimination is the major route; dose adjustment required in renal impairment (CrCl <30 mL/min).
Half-life: Approximately 6–10 hours (active metabolite). Dosing follows product label, typically twice daily for 5 days (treatment) or 10 days (prophylaxis).
Adverse effects
Common (nausea, vomiting):
- Gastrointestinal upset is the most frequent adverse effect
- Taking oseltamivir with food may reduce nausea
- Usually mild and self-limited
Neuropsychiatric events (rare but important):
- Reported in children and adolescents: confusion, delirium, hallucinations, self-injury, seizure
- Causal relationship not established; may be related to severe influenza itself
- FDA warning in 2006; monitor patients, especially children, for behavioral changes
- More common in Japanese populations; genetic variants in metabolism may contribute
Other reported:
- Headache, fatigue, diarrhea
- Allergic reactions (rash, bronchospasm) – rare
- Acute bronchitis, pneumonia (distinguish from influenza progression)
Risk factors for adverse effects: Young age, renal impairment, hepatic disease.
Contraindications and warnings
Contraindications:
- Hypersensitivity to oseltamivir or components of the formulation
Renal impairment:
- Dose reduction required if creatinine clearance <30 mL/min
- Active metabolite accumulates in renal failure; associated with increased adverse effects including neuropsychiatric events
Black box warning:
- None; however, FDA warning for neuropsychiatric complications in children and adolescents
Cautions:
- Pregnancy: Category C; use only if potential benefit justifies risk. Limited data; oseltamivir crosses placenta but teratogenicity not established. Consider in pregnant women at high risk for severe influenza (second and third trimester favored)
- Breastfeeding: Active metabolite excreted in breast milk in low concentrations; generally considered acceptable
- Hepatic disease: Use with caution; hepatic esterases required for prodrug activation
- Monitoring: Observe for behavioral changes, especially in children and adolescents
Note: Unlike inhaled zanamivir, which may worsen bronchospasm in patients with asthma or COPD, oseltamivir is safe and actually preferred for influenza patients with underlying respiratory disease.
Drug interactions
Limited clinically significant interactions:
Esterase-dependent metabolism:
- Oseltamivir activation depends on hepatic and intestinal esterases; potential for competition with other ester prodrugs is theoretical
- No significant clinically relevant interactions identified with common medications
Renal elimination:
- Active metabolite competes for renal tubular secretion with other renally eliminated drugs
- Co-administration with drugs undergoing active tubular secretion (e.g., probenecid, cimetidine) may increase oseltamivir or competing drug concentrations
- Clinical significance is generally minor
Live attenuated influenza vaccine (LAIV):
- Oseltamivir may inhibit replication of live vaccine virus
- Administer LAIV at least 2 weeks before or 48 hours after oseltamivir; inactivated influenza vaccine is preferred during oseltamivir use
No major interactions with antiretrovirals, anticoagulants, or common chronic medications documented.
Clinical pearls
- Timing is critical: Oseltamivir is most effective when started within 48 hours of symptom onset. Benefit is modest (1–1.5 days symptom reduction) in immunocompetent hosts but may prevent complications in high-risk patients
- Resistance: Neuraminidase inhibitor resistance is uncommon but emerging; H275Y mutation confers oseltamivir resistance in H1N1 (some seasonal strains)
- Not a substitute for vaccination: Oseltamivir is treatment/prophylaxis; annual influenza vaccine remains the cornerstone of prevention
- Post-exposure prophylaxis: Effective for household contacts and close contacts if started within 2 days of last exposure
- Renal dosing is essential: In patients with CrCl <30 mL/min, standard dosing may cause accumulation and neuropsychiatric toxicity
- Distinguish from bacterial superinfection: Monitor for secondary bacterial pneumonia (S. pneumoniae, S. aureus, H. influenzae) which can occur during or after influenza
- Pregnancy consideration: Influenza in pregnant women carries higher risk of severe disease; CDC recommends antiviral treatment if symptomatic, particularly in second/third trimester
- Preferred for patients with asthma/COPD: Unlike inhaled zanamivir, oseltamivir does not cause bronchospasm and is the antiviral of choice in patients with underlying airway disease
OSELTA = Oral neuraminidase Sepsis Ester prodrug Limits Terminal virion release Antiviral Activated in liver (though this is lengthy; no universally standard mnemonic)
Practice questions
1. A 28-year-old previously healthy woman presents with 24 hours of fever, myalgias, and cough. Rapid influenza test is positive for influenza A. She is 6 weeks pregnant. Which of the following is the most appropriate management?
2. A 72-year-old male with COPD and CrCl of 25 mL/min presents with 36 hours of influenza-like illness confirmed by PCR. His son is hospitalized with severe influenza pneumonia. Which dosing adjustment is most appropriate?
3. A 14-year-old boy is prescribed oseltamivir for confirmed influenza and develops confusion, visual hallucinations, and attempts self-injury 2 days into therapy. What is the most likely explanation?
Frequently asked questions
How does oseltamivir work?
Oseltamivir is a prodrug converted to active oseltamivir carboxylate by hepatic esterases. The active form competitively inhibits influenza neuraminidase, preventing cleavage of sialic acid receptors on host cell membranes and blocking release of newly formed viral particles from infected cells.
What are the side effects of oseltamivir?
Nausea and vomiting are the most common adverse effects and usually mild. Rare but serious: neuropsychiatric events (confusion, delirium, hallucinations, self-injury) in children and adolescents. Headache, fatigue, and diarrhea are also reported. Risk of accumulation in renal impairment.
How soon should oseltamivir be started for influenza?
Oseltamivir is most effective when started within 48 hours of symptom onset. Starting treatment within this window reduces symptom duration by approximately 1–2 days and may reduce complications in high-risk patients. It can be considered beyond 48 hours in hospitalized or severely ill patients.
Does oseltamivir resistance exist, and how common is it?
Yes. The H275Y neuraminidase mutation confers oseltamivir resistance, particularly in some H1N1 seasonal strains. Resistance is uncommon but has increased in certain regions and subpopulations. Surveillance is ongoing; zanamivir or peramivir may be alternatives in resistant cases.
Is oseltamivir safe in pregnancy?
Oseltamivir is pregnancy category C. Limited data suggest it is likely safe, and CDC recommends antiviral treatment for symptomatic pregnant women with confirmed or suspected influenza, particularly in the second and third trimesters, as untreated influenza carries higher maternal and fetal risk.
Conditions it is used for
Related drugs
Sources and further reading
DailyMed (FDA labels)StatPearls (NCBI Bookshelf)MedlinePlusWHO ATC/DDD index: J05AH02
Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.